Inactive Instrument

Highlights Willow Biosciences Inc Canadian Securities Exchange

Equities

CA97111B1076

Highlights

Unlock all the news: Be the first to know and act before the market!

Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab	05-30	MT
Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab	05-30	MT
Willow Biosciences Inc. Announces Multi-Product Development and Licensing Partnership with Laurus Labs	05-30	CI
Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	05-13	MT
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024	05-13	CI
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Willow Biosciences Narrows 2023 Loss YOY	04-01	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	03-01	MT
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	01-31	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	01-31	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	01-31	CI
Willow Biosciences Announces Collaboration With Enterin	01-16	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	01-16	CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights	01-10	MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024	01-10	MT
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program	12-07	MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program	12-07	MT
Willow Biosciences Reports Q3 Results, Provides Update	11-15	MT
Willow Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Willow Biosciences Inc Canadian Securities Exchange

Equities

CA97111B1076

Highlights

Filters